NCT06884891View on ClinicalTrials.gov

A Phase Ⅲ Comparative Study of QL2108 to Dupixent®

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

520

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

April 30, 2028

Conditions
Atopic Dermatitis
Interventions
DRUG

QL2108 injection

300mg/2.0mL; an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week (Q2W);subcutaneous injection

DRUG

Dupixent®

300mg/2.0mL; an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week (Q2W); subcutaneous injection

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY